<DOC>
	<DOCNO>NCT02699047</DOCNO>
	<brief_summary>Double-blind , randomize clinical trial ass effect 1,55 g/day n-3 fatty acid fish oil concomitant chemotherapy gastrointestinal cancer .</brief_summary>
	<brief_title>Fish Oil Supplementation Gastrointestinal Cancer</brief_title>
	<detailed_description>This study divide three stage define : baseline ( T0 ) , middle moment ( T1 ) final moment ( T2 ) . At baseline , performer patient identification , clinical data collection , assessment anthropometric data body composition , blood sample collection questionnaires application individual allocate two group ( Fish Oil Group Placebo Group ) . The Fish Oil Group ( GOP ) receive fish oil capsule placebo group ( GP ) receive capsule contain olive oil , also receive consumption guideline . The list randomization generate computer program divide cancer localization gender . The researcher involve recruitment access randomization list contain code . The code distribute sequentially . The baseline day first chemotherapy . In middle moment , five week start study , new blood collection , questionnaires measurement anthropometric data perform . At final moment , nine week baseline , last blood collection , questionnaires measurement anthropometric data body composition fish oil placebo group perform , feature end capsule consumption . After 6 month 1 year initiation chemotherapy supplementation fish oil placebo , survival data collect . Throughout monitor period , researcher collaborator maintain contact individual include . The contact make CEPON , receive chemotherapy , telephone .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Individuals age 18 70 y. Histopathological diagnosis gastric cancer , colorectal anal canal intestinal cancer Ability start chemotherapy institution ( CEPON ) Performance status &lt; = 2 Prior chemotherapy Inability oral intake diagnosis infectious inflammatory disease diabetes Allergy fish / derivative , Pregnant , Treatment statins antiinflammatories drug Intake fish oil and/or another supplement contain omega3 polyunsaturated fatty acid six month prior inclusion study Continued use supplement contain antioxidant Patients palliative care without cognitive ability perform study protocol Enrolled study new drug Hospitalized patient recruitment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gastrointestinal cancer</keyword>
	<keyword>Fish oil</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Quality life</keyword>
	<keyword>Nutritional status</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Stomach cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>polyunsaturated fatty acid n-3</keyword>
</DOC>